Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist.

Medetomidine (4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole) was tested for alpha 2-adrenoceptor agonist activity and compared to several reference agents. In binding studies carried out with rat brain membrane preparations, medetomidine showed high affinity for alpha 2-adrenoceptors, as measured by the displacement of [3H]clonidine (Ki 1.08 nM compared to 1.62, 3.20, 6.22 and 194 nM for detomidine, clonidine, UK 14,304 and xylazine, respectively). The affinity of medetomidine for alpha 1-adrenoceptors, as measured by [3H]prazosin displacement, was much weaker, yielding a relative alpha 2/alpha 1 selectivity ratio of 1620 which is 5-10 times higher than that of the reference compounds. Medetomidine caused a concentration-dependent inhibition of the twitch response in electrically stimulated mouse vas deferens with a pD2 value of 9.0 compared to that of 8.6, 8.5, 8.2 and 7.1 for detomidine, clonidine, UK 14,304 and xylazine, respectively. The effect of medetomidine was antagonized by idazoxan. In anaesthetized rats, medetomidine caused a dose-dependent mydriasis which could be reversed by alpha 2-adrenoceptor blockade. In receptor binding experiments and isolated organs medetomidine had no affinity or effects on beta 1-, beta 2-, H1, H2, 5-HT1, 5-HT2, muscarine, dopamine, tryptamine, GABA, opiate and benzodiazepine receptors. Based on these results, medetomidine can be classified as a potent, selective and specific alpha 2-adrenoceptor agonist.

[1]  D. Redmond.  Does clonidine alter anxiety in humans , 1982 .

[2]  G. M. Drew,et al.  Effects of α-adrenoceptor agonists and antagonists on pre- and postsynaptically located α-adrenoceptors , 1976 .

[3]  W. Pettinger,et al.  A functional basis for classification of α-adrenergic receptors , 1977 .

[4]  J. Viikari,et al.  Sedative and cardiovascular effects of medetomidine, a novel selective alpha 2-adrenoceptor agonist, in healthy volunteers. , 1987, British journal of clinical pharmacology.

[5]  Van Rossum Jm.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. , 1963 .

[6]  V. Saano.  Affinity of various compounds for benzodiazepine binding sites in rat brain, heart and kidneys in vitro. , 2009, Acta pharmacologica et toxicologica.

[7]  H. Ruskoaho,et al.  EVIDENCE FOR MEDETOMIDINE AS A SELECTIVE AND POTENT AGONIST α2‐ADRENORECEPTORS , 1986 .

[8]  D. Bylund,et al.  Characterization of α1-and α2-Adrenergic Receptors , 1983 .

[9]  K. Starke.  Alpha-adrenoceptor subclassification. , 1981, Reviews of physiology, biochemistry and pharmacology.

[10]  K. Starke.  α-Adrenoceptor subclassification , 1981 .

[11]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[12]  W. Pettinger.  Pharmacology of Clonidine , 1980, Journal of cardiovascular pharmacology.

[13]  V. Saano.  Tofizopam affects binding of [3H]muscimol to gamma-amino-butyric acid receptors in rat and mouse brains. , 1982, Pharmacological research communications.

[14]  A. Roach,et al.  α2‐Adrenoceptor agonists induce mydriasis in the rat by an action within the central nervous system , 1983 .

[15]  P. Wood.  Multiple Opioid Receptors in the Central Nervous System , 1986 .

[16]  R. Virtanen,et al.  Evaluation of the α1- and α2-adrenoceptor effects of detomidine, a novel veterinary sedative analgesic , 1985 .

[17]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[18]  L. Tuomisto,et al.  Tremorigenic effect and inhibition of tryptamine and serotonin receptor binding by beta-carbolines. , 1987, Pharmacology & toxicology.

[19]  A. Roach,et al.  Studies on RX 781094: a selective, potent and specific antagonist of α2‐adrenoceptors , 1983 .